title: EP4 receptor as a new target for bronchodilator therapy.
abstract: BACKGROUND
  Asthma and chronic obstructive pulmonary disease are airway inflammatory diseases characterised by airflow obstruction. Currently approved bronchodilators such as long-acting β(2) adrenoceptor agonists are the mainstay treatments but often fail to relieve symptoms of chronic obstructive pulmonary disease and severe asthma and safety concerns have been raised over long-term use. The aim of the study was to identify the receptor involved in prostaglandin E(2) (PGE(2))-induced relaxation in guinea pig, murine, monkey, rat and human airways in vitro.
  
  
  METHODS
  Using an extensive range of pharmacological tools, the relaxant potential of PGE(2) and selective agonists for the EP(1-4) receptors in the presence and absence of selective antagonists in guinea pig, murine, monkey, rat and human isolated airways was investigated.
  
  
  RESULTS
  In agreement with previous studies, it was found that the EP(2) receptor mediates PGE(2)-induced relaxation of guinea pig, murine and monkey trachea and that the EP(4) receptor mediates PGE(2)-induced relaxation of the rat trachea. These data have been confirmed in murine airways from EP(2) receptor-deficient mice (Ptger2). In contrast to previous publications, a role for the EP(4) receptor in relaxant responses in human airways in vitro was found. Relaxant activity of AH13205 (EP(2) agonist) was also demonstrated in guinea pig but not human airway tissue, which may explain its failure in clinical studies.
  
  
  CONCLUSIONS
  Identification of the receptor mediating PGE(2)-induced relaxation represents a key step in developing a novel bronchodilator therapy. These data explain the lack of bronchodilator activity observed with selective EP(2) receptor agonists in clinical studies.
authors: Respiratory Pharmacology, Pharmacology and Toxicology Section, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, Sir Alexander Fleming Building, London SW7 2AZ, UK.
authors: James
authors: J
authors: Buckley
authors: Mark A
authors: MA
authors: Birrell
authors: Sarah A
authors: SA
authors: Maher
authors: Anthony T
authors: AT
authors: Nials
authors: Deborah L
authors: DL
authors: Clarke
authors: Maria G
authors: MG
authors: Belvisi
references: Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41
references: 9537820
references: Eur J Clin Pharmacol. 1973 Aug;6(2):127-32
references: 4588852
references: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:535-56
references: 12432942
references: Annu Rev Pharmacol Toxicol. 2001;41:661-90
references: 11264472
references: Am J Respir Crit Care Med. 1999 Jan;159(1):31-6
references: 9872814
references: Br J Pharmacol. 1994 May;112(1):133-6
references: 8032634
references: Am J Respir Crit Care Med. 2009 Nov 15;180(10):923-8
references: 19729667
references: Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93
references: 10634944
references: Br J Pharmacol Chemother. 1964 Jun;22:511-9
references: 14211681
references: Endocrinology. 2000 Apr;141(4):1554-9
references: 10746663
references: J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S502-19
references: 12592297
references: Nucleic Acids Res. 2009 Jan;37(Database issue):D680-5
references: 18948278
references: Br J Pharmacol. 1999 Feb;126(4):867-72
references: 10193766
references: Mol Pharmacol. 1999 Sep;56(3):545-51
references: 10462542
references: Br J Pharmacol. 2006 Jun;148(3):326-39
references: 16604093
references: Thorax. 1982 Jun;37(6):430-7
references: 7135277
references: Eur Respir J. 2008 Jan;31(1):143-78
references: 18166595
references: J Appl Physiol (1985). 2000 Jun;88(6):2214-8
references: 10846038
references: Am Rev Respir Dis. 1993 Jul;148(1):87-90
references: 8317820
references: Pharmacol Rev. 1994 Jun;46(2):205-29
references: 7938166
references: Br J Pharmacol. 1997 Sep;122(2):217-24
references: 9313928
references: Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
references: 17507545
references: Pharmacol Rev. 1957 Jun;9(2):211-8
references: 13465301
references: J Immunol. 2008 Sep 15;181(6):4265-71
references: 18768884
references: Br J Clin Pharmacol. 1985 Oct;20(4):355-9
references: 3865687
references: Br J Clin Pharmacol. 1981 Nov;12(5):731-5
references: 7332739
references: Chest. 2006 Jan;129(1):15-26
references: 16424409
references: J Clin Invest. 2002 Apr;109(7):883-93
references: 11927615
references: J Pharmacol Exp Ther. 2010 Jul;334(1):53-62
references: 20371707
references: Nature. 1968 Jan 6;217(5123):69
references: 4383955
references: Physiol Rev. 1999 Oct;79(4):1193-226
references: 10508233
references: Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L599-606
references: 12618422
references: Am J Respir Crit Care Med. 1994 May;149(5):1138-41
references: 8173753
references: Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L469-74
references: 11435222